Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

High Levels of Treatment Success and Zero Relapse in Multidrug-Resistant Tuberculosis Patients Receiving a Levofloxacin-Based Shorter Treatment Regimen in Vietnam.

Anh LTN, M V Kumar A, Ramaswamy G, Htun T, Thanh Hoang Thi T, Hoai Nguyen G, Quelapio M, Gebhard A, Nguyen HB, Nguyen NV.

Trop Med Infect Dis. 2020 Mar 10;5(1). pii: E43. doi: 10.3390/tropicalmed5010043.

2.

Integration of drug safety monitoring in tuberculosis treatment programmes: country experiences.

Tiemersma E, van den Hof S, Dravniece G, Wares F, Molla Y, Permata Y, Lukitosari E, Quelapio M, Aung ST, Aung KM, Thuy HT, Hoa VD, Sulaimanova M, Sagyndikova S, Makhmudova M, Soliev A, Kimerling M.

Eur Respir Rev. 2019 Oct 11;28(153). pii: 180115. doi: 10.1183/16000617.0115-2018. Print 2019 Sep 30. Review.

3.

QTc and anti-tuberculosis drugs: a perfect storm or a tempest in a teacup? Review of evidence and a risk assessment.

Monedero-Recuero I, Hernando-Marrupe L, Sánchez-Montalvá A, Cox V, Tommasi M, Furin J, Chiang CY, Quelapio M, Koura KG, Trébucq A, Padanilam X, Dravniece G, Piubello A.

Int J Tuberc Lung Dis. 2018 Oct 26. doi: 10.5588/ijtld.18.0423. [Epub ahead of print]

PMID:
30366516
4.

Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method.

Mitnick CD, White RA, Lu C, Rodriguez CA, Bayona J, Becerra MC, Burgos M, Centis R, Cohen T, Cox H, D'Ambrosio L, Danilovitz M, Falzon D, Gelmanova IY, Gler MT, Grinsdale JA, Holtz TH, Keshavjee S, Leimane V, Menzies D, Migliori GB, Milstein MB, Mishustin SP, Pagano M, Quelapio MI, Shean K, Shin SS, Tolman AW, van der Walt ML, Van Deun A, Viiklepp P; Collaborative Group for Analysis of Bacteriology Data in MDR-TB Treatment.

Eur Respir J. 2016 Oct;48(4):1160-1170. doi: 10.1183/13993003.00462-2016. Epub 2016 Sep 1.

5.

Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis: An Individual Patient Data Metaanalysis.

Fox GJ, Mitnick CD, Benedetti A, Chan ED, Becerra M, Chiang CY, Keshavjee S, Koh WJ, Shiraishi Y, Viiklepp P, Yim JJ, Pasvol G, Robert J, Shim TS, Shin SS, Menzies D; Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB, Ahuja S, Ashkin D, Avendaño M, Banerjee R, Bauer M, Burgos M, Centis R, Cobelens F, Cox H, D'Ambrosio L, de Lange WCM, DeRiemer K, Enarson D, Falzon D, Flanagan K, Flood J, Gandhi N, Garcia-Garcia L, Granich RM, Hollm-Delgado MG, Holtz TH, Hopewell P, Iseman M, Jarlsberg LG, Kim HR, Lancaster J, Lange C, Leimane V, Leung CC, Li J, Menzies D, Migliori GB, Narita M, Nathanson E, Odendaal R, O'Riordan P, Pai M, Palmero D, Park SK, Pena J, Pérez-Guzmán C, Ponce-de-Leon A, Quelapio MID, Quy HT, Riekstina V, Royce S, Salim M, Schaaf HS, Seung KJ, Shah L, Shean K, Sifuentes-Osornio J, Sotgiu G, Strand MJ, Sung SW, Tabarsi P, Tupasi TE, Vargas MH, van Altena R, van der Walt M, van der Werf TS, Westenhouse J, Yew WW.

Clin Infect Dis. 2016 Apr 1;62(7):887-895. doi: 10.1093/cid/ciw002. Epub 2016 Jan 12.

PMID:
26757804
6.

Genotypic characteristics of Mycobacterium tuberculosis isolated from household contacts of tuberculosis patients in the Philippines.

Sia IG, Buckwalter SP, Doerr KA, Lugos S, Kramer R, Orillaza-Chi R, Quelapio MI, Tupasi TE, Wengenack NL.

BMC Infect Dis. 2013 Dec 5;13:571. doi: 10.1186/1471-2334-13-571.

7.

Patterns of treatment interruption among patients with multidrug-resistant TB (MDR TB) and association with interim and final treatment outcomes.

Podewils LJ, Gler MT, Quelapio MI, Chen MP.

PLoS One. 2013 Jul 29;8(7):e70064. doi: 10.1371/journal.pone.0070064. Print 2013.

8.

Predictors of sputum culture conversion among patients treated for multidrug-resistant tuberculosis.

Kurbatova EV, Gammino VM, Bayona J, Becerra MC, Danilovitz M, Falzon D, Gelmanova I, Keshavjee S, Leimane V, Mitnick CD, Quelapio MI, Riekstina V, Taylor A, Viiklepp P, Zignol M, Cegielski JP.

Int J Tuberc Lung Dis. 2012 Oct;16(10):1335-43. doi: 10.5588/ijtld.11.0811.

PMID:
23107633
9.

Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients.

Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, Becerra MC, Benedetti A, Burgos M, Centis R, Chan ED, Chiang CY, Cox H, D'Ambrosio L, DeRiemer K, Dung NH, Enarson D, Falzon D, Flanagan K, Flood J, Garcia-Garcia ML, Gandhi N, Granich RM, Hollm-Delgado MG, Holtz TH, Iseman MD, Jarlsberg LG, Keshavjee S, Kim HR, Koh WJ, Lancaster J, Lange C, de Lange WC, Leimane V, Leung CC, Li J, Menzies D, Migliori GB, Mishustin SP, Mitnick CD, Narita M, O'Riordan P, Pai M, Palmero D, Park SK, Pasvol G, Peña J, Pérez-Guzmán C, Quelapio MI, Ponce-de-Leon A, Riekstina V, Robert J, Royce S, Schaaf HS, Seung KJ, Shah L, Shim TS, Shin SS, Shiraishi Y, Sifuentes-Osornio J, Sotgiu G, Strand MJ, Tabarsi P, Tupasi TE, van Altena R, Van der Walt M, Van der Werf TS, Vargas MH, Viiklepp P, Westenhouse J, Yew WW, Yim JJ; Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB.

PLoS Med. 2012;9(8):e1001300. Epub 2012 Aug 28.

10.

Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects.

Kurbatova EV, Taylor A, Gammino VM, Bayona J, Becerra M, Danilovitz M, Falzon D, Gelmanova I, Keshavjee S, Leimane V, Mitnick CD, Quelapio MI, Riekstina V, Viiklepp P, Zignol M, Cegielski JP.

Tuberculosis (Edinb). 2012 Sep;92(5):397-403. doi: 10.1016/j.tube.2012.06.003. Epub 2012 Jul 10.

11.

Impact of patient and program factors on default during treatment of multidrug-resistant tuberculosis.

Gler MT, Podewils LJ, Munez N, Galipot M, Quelapio MI, Tupasi TE.

Int J Tuberc Lung Dis. 2012 Jul;16(7):955-60. doi: 10.5588/ijtld.11.0502. Epub 2012 May 7.

12.

Bacteriologic monitoring of multidrug-resistant tuberculosis patients in five DOTS-Plus pilot projects.

Gammino VM, Taylor AB, Rich ML, Bayona J, Becerra MC, Bonilla C, Gelmanova I, Hollo V, Jaramillo E, Keshavjee S, Leimane V, Mitnick CD, Quelapio MI, Riektsina V, Tupasi TE, Wells CD, Zignol M, Cegielski PJ.

Int J Tuberc Lung Dis. 2011 Oct;15(10):1315-22. doi: 10.5588/ijtld.10.0221.

PMID:
22283887
13.

Frequency and type of microbiological monitoring of multidrug-resistant tuberculosis treatment.

Kurbatova EV, Gammino VM, Bayona J, Becerra M, Danilovitz M, Falzon D, Gelmanova I, Keshavjee S, Leimane V, Mitnick CD, Quelapio MI, Riekstina V, Taylor A, Viiklepp P, Zignol M, Cegielski JP.

Int J Tuberc Lung Dis. 2011 Nov;15(11):1553-5, i. doi: 10.5588/ijtld.11.0101.

PMID:
22008772
14.

WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update.

Falzon D, Jaramillo E, Schünemann HJ, Arentz M, Bauer M, Bayona J, Blanc L, Caminero JA, Daley CL, Duncombe C, Fitzpatrick C, Gebhard A, Getahun H, Henkens M, Holtz TH, Keravec J, Keshavjee S, Khan AJ, Kulier R, Leimane V, Lienhardt C, Lu C, Mariandyshev A, Migliori GB, Mirzayev F, Mitnick CD, Nunn P, Nwagboniwe G, Oxlade O, Palmero D, Pavlinac P, Quelapio MI, Raviglione MC, Rich ML, Royce S, Rüsch-Gerdes S, Salakaia A, Sarin R, Sculier D, Varaine F, Vitoria M, Walson JL, Wares F, Weyer K, White RA, Zignol M.

Eur Respir J. 2011 Sep;38(3):516-28. doi: 10.1183/09031936.00073611. Epub 2011 Aug 4.

15.

Clinical symptoms and microbiological outcomes in tuberculosis treatment trials.

Bark CM, Dietze R, Okwera A, Quelapio MI, Thiel BA, Johnson JL.

Tuberculosis (Edinb). 2011 Nov;91(6):601-4. doi: 10.1016/j.tube.2011.05.007. Epub 2011 Aug 2.

16.

Multidrug-resistant tuberculosis among previously treated patients in the Philippines.

Gler MT, Macalintal LE, Raymond L, Guilatco R, Quelapio MI, Tupasi TE.

Int J Tuberc Lung Dis. 2011 May;15(5):652-6. doi: 10.5588/ijtld.10.0400.

PMID:
21756517
17.

Responding to the multidrug-resistant tuberculosis crisis: mainstreaming programmatic management to the Philippine National Tuberculosis Programme.

Quelapio MI, Mira NR, Orillaza-Chi RB, Belen V, Muñez N, Belchez R, Egos GE, Evangelista M, Vianzon R, Tupasi TE.

Int J Tuberc Lung Dis. 2010 Jun;14(6):751-7.

PMID:
20487615
18.

Significant decline in the tuberculosis burden in the Philippines ten years after initiating DOTS.

Tupasi TE, Radhakrishna S, Chua JA, Mangubat NV, Guilatco R, Galipot M, Ramos G, Quelapio MI, Beltran G, Legaspi J, Vianzon RG, Lagahid J.

Int J Tuberc Lung Dis. 2009 Oct;13(10):1224-30.

PMID:
19793426
19.

Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion.

Johnson JL, Hadad DJ, Dietze R, Maciel EL, Sewali B, Gitta P, Okwera A, Mugerwa RD, Alcaneses MR, Quelapio MI, Tupasi TE, Horter L, Debanne SM, Eisenach KD, Boom WH.

Am J Respir Crit Care Med. 2009 Sep 15;180(6):558-63. doi: 10.1164/rccm.200904-0536OC. Epub 2009 Jun 19.

20.

Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the Philippines.

Tupasi TE, Gupta R, Quelapio MI, Orillaza RB, Mira NR, Mangubat NV, Belen V, Arnisto N, Macalintal L, Arabit M, Lagahid JY, Espinal M, Floyd K.

PLoS Med. 2006 Sep;3(9):e352.

21.

Tuberculosis infection and disease in children living in households of Filipino patients with tuberculosis: a preliminary report.

Salazar-Vergara RM, Sia IG, Tupasi TE, Alcañeses MR, Orillaza RB, Co V, Quelapio MI, Beltran G, Legaspi JD, Rostrata MP, Tecson ME, Corpuz ML.

Int J Tuberc Lung Dis. 2003 Dec;7(12 Suppl 3):S494-500.

PMID:
14677843
22.

DOTS-Plus for multidrug-resistant tuberculosis in the Philippines: global assistance urgently needed.

Tupasi TE, Quelapio MI, Orillaza RB, Alcantara C, Mira NR, Abeleda MR, Belen VT, Arnisto NM, Rivera AB, Grimaldo ER, Derilo JO, Dimarucut W, Arabit M, Urboda D.

Tuberculosis (Edinb). 2003;83(1-3):52-8.

PMID:
12758189
23.

Increased resistance to ciprofloxacin and ofloxacin in multidrug-resistant mycobacterium tuberculosis isolates from patients seen at a tertiary hospital in the Philippines.

Grimaldo ER, Tupasi TE, Rivera AB, Quelapio MI, Cardaño RC, Derilo JO, Belen VA.

Int J Tuberc Lung Dis. 2001 Jun;5(6):546-50.

PMID:
11409582
24.

Bacillary disease and health seeking behavior among Filipinos with symptoms of tuberculosis: implications for control.

Tupasi TE, Radhakrishna S, Co VM, Villa ML, Quelapio MI, Mangubat NV, Sarol JN, Rivera AB, Pascual ML, Reyes AC, Sarmiento A, Solon M, Solon FS, Burton L, Mantala MJ.

Int J Tuberc Lung Dis. 2000 Dec;4(12):1126-32.

PMID:
11144454
25.

BCG coverage and the annual risk of tuberculosis infection over a 14-year period in the Philippines assessed from the Nationwide Prevalence Surveys.

Tupasi TE, Radhakrishna S, Pascual ML, Quelapio MI, Villa ML, Co VM, Sarol J, Mangubat N, Reyes AC, Sarmiento A, Solon M, Solon F, Burton L, Lofranco VS, Rostrata MP, Mantala MJ.

Int J Tuberc Lung Dis. 2000 Mar;4(3):216-22.

PMID:
10751066
26.

Tuberculosis in the urban poor settlements in the Philippines.

Tupasi TE, Radhakrishna S, Quelapio MI, Villa ML, Pascual ML, Rivera AB, Sarmiento A, Co VM, Sarol JN, Beltran G, Legaspi JD, Mangubat NV, Reyes AC, Solon M, Solon FS, Burton L, Mantala MJ.

Int J Tuberc Lung Dis. 2000 Jan;4(1):4-11.

PMID:
10654637
27.

The 1997 Nationwide Tuberculosis Prevalence Survey in the Philippines.

Tupasi TE, Radhakrishna S, Rivera AB, Pascual ML, Quelapio MI, Co VM, Villa ML, Beltran G, Legaspi JD, Mangubat NV, Sarol JN Jr, Reyes AC, Sarmiento A, Solon M, Solon FS, Mantala MJ.

Int J Tuberc Lung Dis. 1999 Jun;3(6):471-7.

PMID:
10383058

Supplemental Content

Loading ...
Support Center